Coronary stent prices in India: the 2017 NPPA cap, what the law actually allows, and what your bill should show
In 2017 NPPA capped coronary stents and prices crashed 85%. Eight years on, the ceiling still binds — but hospitals have found other lines to add. Here's the current cap, the four common overcharges that work around it, and what a clean stent bill looks like.
Published · Jaanch
Few NPPA orders have ever moved as much money as the coronary stent ceiling that came into force in February 2017. Before the order, a single drug-eluting stent in a Delhi private hospital ran anywhere from Rs 90,000 to Rs 1.9 lakh. After the order, the legal maximum crashed to Rs 29,600. That's roughly an 85% drop. Across the cardiac sector, NPPA estimated that patients save over Rs 4,400 crore a year.
But cardiac billing didn't just give up. Within a few months of the order, the patterns shifted. Patients started seeing handling charges re-introduced, ancillary procedure fees re-priced, post-procedure medications doubled. The stent line itself was usually compliant, but the bill total didn't move as much as the headline cap suggested it should.
Eight years on, the ceiling is still in force, and the workarounds are still active. This is the patient's guide to what should be there and what shouldn't.
What the 2017 order actually did
The original order — DPCO 2013, schedule revision via Notification S.O. 522(E) — defined two classes of coronary stent:
- Bare-metal stent (BMS) — older technology, plain stainless steel or cobalt alloy. The ceiling was set at Rs 7,260 per unit.
- Drug-eluting stent (DES) — the modern standard, with a polymer coating that releases an anti-proliferative drug. The ceiling was set at Rs 29,600 per unit.
Both are per-unit ceilings, exclusive of GST. The order applied to all manufacturers and importers, so the cap took effect across imported premium stents (Abbott Xience, Medtronic Resolute, Boston Scientific Synergy) and Indian-manufactured stents alike.
The category was on the National List of Essential Medicines (NLEM) at the time, which is what gave NPPA the statutory hook.
The current ceiling
NPPA revises the ceiling periodically based on the WPI adjustment and occasional special orders. The 2024 revision puts the current numbers at roughly:
| Stent class | Current ceiling (Rs per unit) |
|---|---|
| Bare-metal (BMS) | ~7,500 |
| Drug-eluting (DES) | ~33,000 |
The 30% margin our audit engine uses (NPPA rule fires when the unit price is more than 1.3 times the ceiling) means a bill showing Rs 43,000 for a single DES would trigger the flag. The cleanest version of this overcharge — the hospital straight-up billing above the ceiling — has become rarer over the years. Most large hospitals caught up.
The four common workarounds
What we see now, in roughly descending order of frequency:
1. Bare-metal billed as drug-eluting
The bill prints a stent at Rs 30,000, calling it a drug-eluting stent. The actual product implanted, per the procedure note, was a bare-metal stent. The DES ceiling is roughly 4x the BMS ceiling, so this is a substantial overcharge if you can prove the substitution.
The discharge summary and the operative note carry the device information. The brand name and lot number are usually printed. If the bill claims DES but the operative note shows a stainless steel BMS, that's a documentable dispute.
2. Multiple stents charged as a procedure premium
When a patient needs two or three stents in the same procedure (which is common in multi-vessel disease), the bill sometimes prints a single "complex angioplasty" line for an inflated amount instead of breaking out two or three stent lines at the ceiling. The complex angioplasty line ends up well above 2x or 3x the ceiling, and the patient has no way to verify what's inside it.
The dispute language: "Could you break out the stent line items separately, each at its NPPA-notified ceiling, and itemise the procedure fee separately?"
3. Handling, deployment, or balloon charges
Some bills carry a separate "stent handling charge" or "balloon inflation charge" or "device deployment fee" line in addition to the stent itself. The NPPA ceiling is a per-unit retail ceiling for the device. Handling and deployment are part of the procedure, not the device. So these should either be zero or rolled into the surgery line.
When we audit, a handling charge that comes to 10% or 20% of the stent ceiling is the usual giveaway. The legitimate procedure line should be billed at the CGHS-equivalent rate for angioplasty, separately from the device.
4. Premium imported stent fee
A specific version of the handling charge. The bill prints the stent at the legal ceiling, then adds a "premium imported brand surcharge" or "international stent supplement" line for Rs 15,000 or more. The NPPA ceiling is a hard ceiling — it doesn't have a premium-for-imports escape. Importer or manufacturer of the stent is irrelevant to whether the ceiling applies.
The dispute on this line is the cleanest. NPPA has been explicit in clarifications that the ceiling is the maximum, period.
What a clean stent bill should look like
For a single-vessel angioplasty with one drug-eluting stent in a Tier 1 private hospital, the line items should approximate:
| Line | Amount (Rs) |
|---|---|
| Coronary angioplasty procedure (CGHS Tier 1 NABH rate) | 91,000 |
| Drug-eluting stent × 1 (at NPPA ceiling) | 33,000 |
| Catheter and guidewires (consumables) | ~20,000 |
| Cath lab utilisation | included in procedure |
| Anaesthesia and OT | included in procedure |
| Per-day room rent (post-op) × n days | per stay |
So the device-related total should be in the Rs 50,000–55,000 range. The procedure rate is separate. Anything substantially above this deserves a closer look.
What NPPA still doesn't cover
A few things to be honest about.
Stent-related consumables. The catheters, guidewires, balloon dilation catheters, and contrast media used in the procedure are medical devices but not coronary stents. NPPA hasn't capped them all. They're billed at retail with a hospital markup, which is legal. A catheter at Rs 8,000 is normal; a catheter at Rs 25,000 might warrant a question.
Post-procedure medications. Dual antiplatelet therapy (aspirin + clopidogrel or ticagrelor) is essential after a stent. The drugs are NPPA-scheduled and have their own ceilings, but they're separate from the stent. Our brand-vs-generic post has the relevant brand mappings.
Cath lab and OT charges. These get folded into the CGHS procedure rate when CGHS rates apply, but private hospitals often bill them separately as "infrastructure fees". This is grey area. CGHS treats them as included; private hospital tariff cards usually carry them separately.
Asking for the bill correction
The reliable approach:
"Could you confirm the per-unit price billed for the stent? Per the NPPA notification, the ceiling for a drug-eluting coronary stent is Rs 33,000 inclusive of all handling and deployment costs. If the billed amount exceeds this ceiling, could the line be corrected?"
If the stent line is already at the ceiling but you see handling / deployment / imported-premium charges separately, the second ask:
"Could you remove or roll into the procedure line the handling/deployment charges associated with the stent? Per NPPA's clarifications, the ceiling is inclusive of these costs and they cannot be billed as additional line items."
The relevant notification numbers to attach: DPCO 2013 and the current NPPA order setting the coronary stent ceiling (referenced in any NPPA-aligned bill in the legal source field).
If the desk refuses, the escalation route covers what comes next. For stent-specific complaints, NPPA itself runs a complaint redressal cell that takes patient complaints directly.
Sources: DPCO 2013; NPPA order Notification S.O. 522(E) and subsequent revisions; NPPA Pharma Sahi Daam database. The numbers in this post are illustrative and should be verified against the current notification before relying on them in a dispute.